{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:44:02Z","timestamp":1770770642823,"version":"3.50.0"},"reference-count":17,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Clin Pharmacol"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:p>Herpes simplex virus (HSV) may cause recurring oral or genital ulcers. We report a series of patients nonresponsive to suppressive valacyclovir therapy, explained by subtherapeutic acyclovir plasma levels. After a dose increase, or in some patients only after concomitant prescription of cimetidine, adequate levels were reached associated with significant clinical improvement.<\/jats:p>","DOI":"10.1002\/bcp.70313","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T10:47:06Z","timestamp":1767005226000},"page":"300-304","source":"Crossref","is-referenced-by-count":0,"title":["Use of cimetidine to enhance systemic acyclovir concentrations in patients with ineffective suppressive therapy for recurring herpes simplex virus infections: A novel purpose for an old drug"],"prefix":"10.1002","volume":"92","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8468-2883","authenticated-orcid":false,"given":"Dominique G.","family":"Stuijt","sequence":"first","affiliation":[{"name":"Department of Infection &amp; Immunity Centre for Human Drug Research (CHDR)  Leiden The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor M.","family":"Cnossen","sequence":"additional","affiliation":[{"name":"Department of Infection &amp; Immunity Centre for Human Drug Research (CHDR)  Leiden The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amira F. Y. S. M.","family":"Osman","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Toxicology Leiden University Medical Center  Leiden The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5980-6947","authenticated-orcid":false,"given":"Teun","family":"van Gelder","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Toxicology Leiden University Medical Center  Leiden The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra M.","family":"Arend","sequence":"additional","affiliation":[{"name":"Leiden University Centre for Infectious Diseases (LU\u2010CID) Leiden University Medical Centre  Leiden The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,12,29]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197707142970201"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007435\u2010198501000\u201000007"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1086\/515385"},{"key":"e_1_2_7_5_1","unstructured":"Herpes \u2010 STI Treatment Guidelines [Internet].2022[cited 2025 July 25]. Available from:https:\/\/www.cdc.gov\/std\/treatment-guidelines\/herpes.htm"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20450"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009036.pub2"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.12.2759"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1993.196"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1177\/106002808501900703"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.21.5.804"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.111.042036"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15538"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.2.458\u2010463.2002"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.4172\/2153\u20100645.1000e127"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.2133\/dmpk.23.306"},{"key":"e_1_2_7_17_1","first-page":"827","volume-title":"Stockley's drug interactions","author":"Baxter K"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2012.12.008"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70313","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/bcp.70313","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70313","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T05:35:53Z","timestamp":1769146553000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1002\/bcp.70313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,29]]},"references-count":17,"aliases":["10.1111\/bcp.70313"],"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1002\/bcp.70313"],"URL":"https:\/\/doi.org\/10.1002\/bcp.70313","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,29]]}}}